Cargando…

A prospective study revealing the role of an immune-related eRNA, WAKMAR2, in breast cancer

Enhancer RNAs (eRNAs) are a subclass of non-coding RNAs that are generated during the transcription of enhancer regions and play an important role in tumourigenesis. In this study, we focused on the crucial eRNAs that participate in immune responses in invasive breast cancer (IBC). We first used The...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Linbang, Liu, Jingkun, Tai, Jiaojiao, Zhou, Nian, Huang, Tianji, Xue, Yuzhou, Quan, Zhengxue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319425/
https://www.ncbi.nlm.nih.gov/pubmed/34321580
http://dx.doi.org/10.1038/s41598-021-94784-3
_version_ 1783730445176799232
author Wang, Linbang
Liu, Jingkun
Tai, Jiaojiao
Zhou, Nian
Huang, Tianji
Xue, Yuzhou
Quan, Zhengxue
author_facet Wang, Linbang
Liu, Jingkun
Tai, Jiaojiao
Zhou, Nian
Huang, Tianji
Xue, Yuzhou
Quan, Zhengxue
author_sort Wang, Linbang
collection PubMed
description Enhancer RNAs (eRNAs) are a subclass of non-coding RNAs that are generated during the transcription of enhancer regions and play an important role in tumourigenesis. In this study, we focused on the crucial eRNAs that participate in immune responses in invasive breast cancer (IBC). We first used The Cancer Genome Atlas and Human enhancer RNA Atlas to screen for tissue-specific eRNAs and their target genes. Through Pearson correlation analysis with immune genes, the eRNA WAKMAR2 was identified as a key candidate involved in IBC. Our further research suggested that WAKMAR2 is crucial in regulating the tumour microenvironment and may function by regulating immune-related genes, including IL27RA, RAC2, FABP7, IGLV1-51, IGHA1, and IGHD. Quantitative reverse transcription-polymerase chain reaction was used to detect the expression of WAKMAR2 in IBC and normal tissues, and the effect of WAKMAR2 on the regulation of downstream genes in MB-231 and MCF7 cells was studied in vitro. WAKMAR2 was found to be highly involved in tumour immunity and was downregulated in IBC tissues. Furthermore, the expression of WAKMAR2 and its target genes was observed at the pan-cancer level. This study provides evidence to suggest new potential targets for the treatment of breast cancer.
format Online
Article
Text
id pubmed-8319425
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-83194252021-07-30 A prospective study revealing the role of an immune-related eRNA, WAKMAR2, in breast cancer Wang, Linbang Liu, Jingkun Tai, Jiaojiao Zhou, Nian Huang, Tianji Xue, Yuzhou Quan, Zhengxue Sci Rep Article Enhancer RNAs (eRNAs) are a subclass of non-coding RNAs that are generated during the transcription of enhancer regions and play an important role in tumourigenesis. In this study, we focused on the crucial eRNAs that participate in immune responses in invasive breast cancer (IBC). We first used The Cancer Genome Atlas and Human enhancer RNA Atlas to screen for tissue-specific eRNAs and their target genes. Through Pearson correlation analysis with immune genes, the eRNA WAKMAR2 was identified as a key candidate involved in IBC. Our further research suggested that WAKMAR2 is crucial in regulating the tumour microenvironment and may function by regulating immune-related genes, including IL27RA, RAC2, FABP7, IGLV1-51, IGHA1, and IGHD. Quantitative reverse transcription-polymerase chain reaction was used to detect the expression of WAKMAR2 in IBC and normal tissues, and the effect of WAKMAR2 on the regulation of downstream genes in MB-231 and MCF7 cells was studied in vitro. WAKMAR2 was found to be highly involved in tumour immunity and was downregulated in IBC tissues. Furthermore, the expression of WAKMAR2 and its target genes was observed at the pan-cancer level. This study provides evidence to suggest new potential targets for the treatment of breast cancer. Nature Publishing Group UK 2021-07-28 /pmc/articles/PMC8319425/ /pubmed/34321580 http://dx.doi.org/10.1038/s41598-021-94784-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Wang, Linbang
Liu, Jingkun
Tai, Jiaojiao
Zhou, Nian
Huang, Tianji
Xue, Yuzhou
Quan, Zhengxue
A prospective study revealing the role of an immune-related eRNA, WAKMAR2, in breast cancer
title A prospective study revealing the role of an immune-related eRNA, WAKMAR2, in breast cancer
title_full A prospective study revealing the role of an immune-related eRNA, WAKMAR2, in breast cancer
title_fullStr A prospective study revealing the role of an immune-related eRNA, WAKMAR2, in breast cancer
title_full_unstemmed A prospective study revealing the role of an immune-related eRNA, WAKMAR2, in breast cancer
title_short A prospective study revealing the role of an immune-related eRNA, WAKMAR2, in breast cancer
title_sort prospective study revealing the role of an immune-related erna, wakmar2, in breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319425/
https://www.ncbi.nlm.nih.gov/pubmed/34321580
http://dx.doi.org/10.1038/s41598-021-94784-3
work_keys_str_mv AT wanglinbang aprospectivestudyrevealingtheroleofanimmunerelatedernawakmar2inbreastcancer
AT liujingkun aprospectivestudyrevealingtheroleofanimmunerelatedernawakmar2inbreastcancer
AT taijiaojiao aprospectivestudyrevealingtheroleofanimmunerelatedernawakmar2inbreastcancer
AT zhounian aprospectivestudyrevealingtheroleofanimmunerelatedernawakmar2inbreastcancer
AT huangtianji aprospectivestudyrevealingtheroleofanimmunerelatedernawakmar2inbreastcancer
AT xueyuzhou aprospectivestudyrevealingtheroleofanimmunerelatedernawakmar2inbreastcancer
AT quanzhengxue aprospectivestudyrevealingtheroleofanimmunerelatedernawakmar2inbreastcancer
AT wanglinbang prospectivestudyrevealingtheroleofanimmunerelatedernawakmar2inbreastcancer
AT liujingkun prospectivestudyrevealingtheroleofanimmunerelatedernawakmar2inbreastcancer
AT taijiaojiao prospectivestudyrevealingtheroleofanimmunerelatedernawakmar2inbreastcancer
AT zhounian prospectivestudyrevealingtheroleofanimmunerelatedernawakmar2inbreastcancer
AT huangtianji prospectivestudyrevealingtheroleofanimmunerelatedernawakmar2inbreastcancer
AT xueyuzhou prospectivestudyrevealingtheroleofanimmunerelatedernawakmar2inbreastcancer
AT quanzhengxue prospectivestudyrevealingtheroleofanimmunerelatedernawakmar2inbreastcancer